Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Non Operating Income (2016 - 2025)

Ani Pharmaceuticals' Non Operating Income history spans 14 years, with the latest figure at $850000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income rose 161.68% year-over-year to $850000.0; the TTM value through Dec 2025 reached $1.9 million, up 147.95%, while the annual FY2025 figure was $1.9 million, 147.95% up from the prior year.
  • Non Operating Income for Q4 2025 was $850000.0 at Ani Pharmaceuticals, up from -$853000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.7 million in Q2 2025 and bottomed at -$2.7 million in Q4 2021.
  • The 5-year median for Non Operating Income is -$47500.0 (2022), against an average of -$296550.0.
  • The largest annual shift saw Non Operating Income plummeted 6400.0% in 2024 before it soared 2076.14% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$2.7 million in 2021, then soared by 98.44% to -$42000.0 in 2022, then increased by 21.43% to -$33000.0 in 2023, then plummeted by 4075.76% to -$1.4 million in 2024, then skyrocketed by 161.68% to $850000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Non Operating Income are $850000.0 (Q4 2025), -$853000.0 (Q3 2025), and $1.7 million (Q2 2025).